Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology — San Antonio, Texas

Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology is a clinical research site located in San Antonio, Texas, United States 78229.

Crixeo Health Trust Score: 56/100 (POOR). This profile has not yet been claimed by the site owner.

Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology has participated in 1 clinical trials.

Therapeutic areas: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer.

Sponsors: Carrick Therapeutics Limited.

Sponsor Feasibility Report

Trust Score: 56/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology?

Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology has a Crixeo Trust Score of 56/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology conducted?

Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology has 1 clinical trials on record. Their work covers Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer.

Is Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology accredited by Crixeo Health?

Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.